Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.

Molecular & cellular proteomics : MCP - 1 Mar 2023

Murray Heather C, Miller Kasey, Brzozowski Joshua S, Kahl Richard G S, Smith Nathan D, Humphrey Sean J, Dun Matthew D, Verrills Nicole M

Abstract excerpt

Acute myeloid leukemia (AML) is the most common and aggressive form of acute leukemia, with a 5-year survival rate of just 24%. Over a third of all AML patients harbor activating mutations in kinases, such as the receptor tyrosine kinases FLT3 (receptor-type tyrosine-protein kinase FLT3) and KIT (mast/stem cell growth factor receptor kit). FLT3 and KIT mutations are associated with poor clinical outcomes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to DNA-Activated Protein Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Receptor Protein-Tyrosine Kinases

Share to Serine

Share to Threonine

Share to TOR Serine-Threonine Kinases

Share to Tyrosine

Source

Open in PubMed Open full text

Identifiers

PMID: 36682716
DOI: 10.1016/j.mcpro.2023.100503
PMCID: PMC9986649

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.PMID 36682716Read ↗

Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.Semantic proximity Read ↗

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemiaSemantic proximity Read ↗

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaSemantic proximity Read ↗

Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cellsSemantic proximity Read ↗

Targeted signal transduction therapies in myeloid malignancies.Semantic proximity Read ↗

Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistanceSemantic proximity Read ↗

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.Semantic proximity Read ↗

Pharmaco-phosphoproteomic analysis of cancer-associated KIT mutations D816V and V560G.Semantic proximity Read ↗

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsSemantic proximity Read ↗

DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: Implications for clonal evolution and disease progression.Semantic proximity Read ↗

Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.Semantic proximity Read ↗

Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.